Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

Company Overview - Rein Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for orphan pulmonary and fibrosis indications [3] - The company's lead product candidate, LTI-03, is a synthetic peptide targeting alveolar epithelial cell survival and inhibiting profibrotic signaling [3] - LTI-03 is expected to enter Phase 2 clinical trials for idiopathic pulmonary fibrosis in the first half of 2025 [3] - The second product candidate, LTI-01, has completed Phase 1b and Phase 2a trials for loculated pleural effusions and has received Orphan Drug Designation in both the U.S. and E.U. as well as Fast Track Designation in the U.S. [3] Upcoming Events - Brian Windsor, Ph.D., President and CEO of Rein Therapeutics, will present at The Citizens Life Sciences Conference 2025 on May 8, 2025, at 12:00 p.m. EDT in New York, NY [1] - A live webcast of the presentation will be available, with a replay accessible for 90 days post-event [2]